Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: Results of a randomized, double-blind, double-dummy, controlled clinical trial

Journal of Hepatology

Volumn 38, Issue 1, 2003, Pages 51-58

  Mas, Antoni ^a,i   Rodés, Juan ^a   Sunyer, Lourdes ^b   Rodrigo, Luís ^c   Planas, Ramon ^d   Vargas, Victor ^e   Castells, Lluís ^e   Rodríguez Martínez, Dolores ^f   Fernández Rodríguez, Conrado ^f   Coll, Ignasi ^g   Pardo, Albert ^h  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Laboratories Zambon SA   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f HOSPITAL XERAL CÍES   (Spain)

^g HOSPITAL MÚTUA DE TERRASSA   (Spain)

^h HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

ⁱ HOSPITAL CLÍNIC   (Spain)

Author keywords

Cirrhosis; Hepatic encephalopathy; Lactitol; Rifaximin

Indexed keywords

LACTITOL; RIFAXIMIN;

ABDOMINAL PAIN; ACUTE DISEASE; ADULT; AGED; AMMONIA BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EEG ABNORMALITY; FEMALE; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PORTAL VEIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; VOMITING;

ACUTE DISEASE; AMMONIA; ANTI-INFECTIVE AGENTS; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; FEMALE; HEPATIC ENCEPHALOPATHY; HUMANS; MALE; MIDDLE AGED; RECURRENCE; RIFAMYCINS; SEVERITY OF ILLNESS INDEX; SUGAR ALCOHOLS; TREATMENT OUTCOME;

EID: 0037232911     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(02)00350-1     Document Type: Article

References (21)

1. Conn HO. The hepatic encephalopathies. In: Conn HO, Bircher J, editors. Hepatic encephalopathy: management with lactulose and related carbohydrates, East Lansing, MI: Medi-Ed Press, 1988. pp. 3-14.
2. Butterworth RE, Gigione JF, Michaud CD, Lavole J, Layrargues GP. Ammonia: key factor in the pathogenesis of hepatic encephalopathy. Neurochem Pathol 1987;6:1-12.
3. Soeters PB, van Leuwen PAM, van Berlo CLH. Nitrogen metabolism in the gut. In: Conn HO, Bircher J, editors. Hepatic encephalopathy: management with lactulose and related carbohydrates, East Lansing, MI: Medi-Ed Press, 1988. pp. 31-39.
4. Blei AT. Hepatic encephalopathy. In: Bircher J, Benhamou JP, McIntyre N, Rizzetto M, Rodés J, editors. Oxford textbook of clinical hepatology, 2nd ed.. Oxford: Oxford Medical, 1998. pp. 765-783.
5. Riordan SM, Williams R. Treatment of hepatic encephalopathy. N Engl J Med 1997;337:473-479.
6. Butterworth RF. Complications of cirrhosis III. Hepatic encephalopathy. J Hepatol 2000;32(Suppl 1):171-180.
7. Bosch J, Bruix J, Mas A, Navasa M, Rodés J. Rolling review: the treatment of major complications of cirrhosis. Aliment Pharmacol Ther 1994;8:639-657.
8. Conn HO, Leevy CM, Vhlacevic ZR, Rodgers JB, Maddrey WB, Seeff L, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double-blind controlled trial. Gastroenterology 1977;72:573-583.
9. Mullen KD, Dasarathy S. Hepatic encephalopathy. In: Schiff ER, Sorrell MF, Maddrey WC, editors. Schiff's diseases of the liver, 8th ed.. Philadelphia, PA: Lippincott-Raven, 1999. pp. 545-581.
10. Venturini AP, Marchi E. In vitro and in vivo evaluation of L/105, a new topical intestinal rifamycin. Chemotherapia 1986;5:257-262.
11. Hoover WW, Gerlach EH, Hoban DJ, Eliopoulos GM, Pfaller MA, Jones RN. Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagn Microbiol Infect Dis 1993;16:111-118.
12. Gillis JC, Brogden RN. Rifaximin: a review of its antibacterial activity, pharmacokinetics properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995;49:467-484.
13. Descombe JJ, Dubourg D, Picard M, Palazzini E. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res 1994;14:51-56.
14. Testa R, Eftimiadi C, Sukkar GS, De Leo C, Rovida S, Schito GC, et al. A non-absorbable rifamycin for the treatment of hepatic encephalopathy. Drugs Exp Clin Res 1985;11:387-392.
15. Di Piazza S, Gabriella Filippazzo M, Valenza LM, Morello S, Pastore L, Conti A, et al. Rifaximine versus neomycin in the treatment of portosystemic encephalopathy. Ital J Gastroenterol 1991;23:403-407.
16. Pedretti G, Calzetti C, Missale G, Fiaccadori F. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhosis. A double-blind, randomized trial. Ital J Gastroenterol 1991;23:175-178.
17. Bucci L, Palmieri GC. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree of hepatic encephalopathy. Curr Med Res Opin 1993;13:109-118.
18. Puxeddu A, Quartini M, Massimetti A, Ferrieri A. Rifaximin in the treatment of chronic hepatic encephalopathy. Curr Med Res Opin 1995;13:278-281.
19. Williams R, James OFW, Warnes TW, Morgan MY. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur J Gastroenterol Hepatol 2000;12:203-208.
20. Corazza GR, Sorge M, Strocchi A, Benati G, Di Sario A, Treggiari EA, et al. Non-absorbable antibiotics and small bowel bacterial over-growth. Ital J Gastroenterol 1992;24(9 Suppl 2):4-9.
21. Di Stefano M, Strocchi A, Malservisi S, Veneto G, Ferrieri A, Corazza GR. Non-absorbable antibiotics for managing intestinal gas production and gas-related syndromes. Aliment Pharmacol Ther 2000;14:1001-1008.